Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

881 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis.
Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H. Hamadani M, et al. Among authors: sureda a. Biol Blood Marrow Transplant. 2017 May;23(5):853-856. doi: 10.1016/j.bbmt.2017.01.082. Epub 2017 Feb 1. Biol Blood Marrow Transplant. 2017. PMID: 28161608 Free PMC article.
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R, Pérez-Simón JA, Moreno E, Queraltó JM, Caballero D, Mateos M, Sureda A, Cañizo C, Brunet S, Briones J, Vazquez L, Clopés A, San Miguel JF, Sierra J. Martino R, et al. Among authors: sureda a. Biol Blood Marrow Transplant. 2005 Jun;11(6):437-47. doi: 10.1016/j.bbmt.2005.03.003. Biol Blood Marrow Transplant. 2005. PMID: 15931632 Free article.
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Alvarez I, et al. Among authors: sureda a. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. doi: 10.1016/j.bbmt.2005.09.009. Biol Blood Marrow Transplant. 2006. PMID: 16443515 Free article. Clinical Trial.
Allogeneic transplantation in lymphoma: current status.
Schmitz N, Dreger P, Glass B, Sureda A. Schmitz N, et al. Among authors: sureda a. Haematologica. 2007 Nov;92(11):1533-48. doi: 10.3324/haematol.11185. Haematologica. 2007. PMID: 18024402 Free article. Review.
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N. Sureda A, et al. J Clin Oncol. 2008 Jan 20;26(3):455-62. doi: 10.1200/JCO.2007.13.2415. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086796
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, González JD, Díaz-Mediavilla J, Hernández B, García-Frade J, Carrera D, León A, Hernández M, Abellán PF, Bergua JM, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). Rosiñol L, et al. Among authors: sureda a. Blood. 2008 Nov 1;112(9):3591-3. doi: 10.1182/blood-2008-02-141598. Epub 2008 Jul 8. Blood. 2008. PMID: 18612103 Free article. Clinical Trial.
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S. Delgado J, et al. Among authors: sureda a. Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001. Biol Blood Marrow Transplant. 2008. PMID: 18940684 Free article.
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL, Valcárcel D, Martino R, Barba P, Moreno E, Sureda A, Vega M, Delgado J, Briones J, Brunet S, Sierra J. Piñana JL, et al. Among authors: sureda a. Biol Blood Marrow Transplant. 2009 Jan;15(1):21-9. doi: 10.1016/j.bbmt.2008.10.011. Biol Blood Marrow Transplant. 2009. PMID: 19135939 Free article.
881 results